XLV — State Street Health Care Select Sector SPDR ETF
Healthcare Ranked #58 of 458 tracked ETFs · Issued by State Street Investment Management
XLV Price Performance — Growth of $10,000
Value of a $10,000 investment in XLV over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
XLV Drawdown
The "underwater" chart: XLV's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in XLV?
See what a lump sum in XLV would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The State Street Health Care Select Sector SPDR ETF (XLV) is a healthcare sector fund managed by State Street Investment Management. With assets under management totaling $40.6 billion, the fund represents significant investor adoption within its category. It currently holds an overall rank of #58 out of 458 tracked ETFs across all categories and has received an ETFValuer grade of B with a score of 73.7. The fund charges an expense ratio of 0.08% and offers a dividend yield of 1.11%. It trades at a price of $167.26 and is one of 11 ETFs tracked by ETFValuer in the Healthcare category. The combination of high assets and a moderate expense ratio suggests a mature vehicle for sector exposure.
Over the last day, the fund gained 2.36%, followed by a 4.37% increase over one week. Monthly returns show a 4.32% gain, while the three-month period saw a significant acceleration to 17.10%. Year-to-date performance stands at 8.47%, and the one-year return reached 24.69%. Longer-term data indicates a 31.71% return over the past three years. The return pattern demonstrates strong momentum over the three-month and one-year horizons compared to the more modest year-to-date figure.
XLV carries a moderate volatility label and a beta of 0.51, indicating lower sensitivity to market movements than the broader market. The fund has generated a Sharpe ratio of 1.24, reflecting efficient risk-adjusted returns relative to its volatility. During market downturns, the fund experienced a maximum drawdown of -17.11%. This combination of a low beta and moderate volatility suggests the fund may offer downside protection while still participating in market gains. The Sharpe ratio further supports the view that the returns achieved have compensated well for the level of risk taken.
AI-generated summary based on the data on this page.
XLV Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | Eli Lilly & Co | 13.74% | $5.30B |
| 2 | Johnson & Johnson | 11.10% | $4.29B |
| 3 | AbbVie Inc | 7.25% | $2.80B |
| 4 | Merck & Co Inc | 5.63% | $2.17B |
| 5 | UnitedHealth Group Inc | 4.62% | $1.78B |
| 6 | Amgen Inc | 3.57% | $1.38B |
| 7 | Thermo Fisher Scientific Inc | 3.48% | $1.34B |
| 8 | Abbott Laboratories | 3.37% | $1.30B |
| 9 | Gilead Sciences Inc | 3.26% | $1.26B |
| 10 | Intuitive Surgical Inc | 3.09% | $1.19B |
Holdings as of 2026-03-31 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 59.1% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how XLV's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With XLV
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with XLV's top 10 — VHT overlaps most, holding 10 of the same companies as XLV's top 10 (59.1% of XLV's assets).
| ETF | Name | Shared Companies | XLV Weight | Examples |
|---|---|---|---|---|
| VHT | Vanguard Health Care Index Fund ETF Shares | 10 | 59.1% | Eli Lilly & Co, Johnson & Johnson, AbbVie Inc… |
| FHLC | Fidelity MSCI Health Care Index ETF | 10 | 59.1% | Eli Lilly & Co, Johnson & Johnson, AbbVie Inc… |
| IYH | iShares U.S. Healthcare ETF | 9 | 45.4% | Johnson & Johnson, AbbVie Inc, UnitedHealth Group Inc… |
| PPH | VanEck Pharmaceutical ETF | 3 | 30.5% | Eli Lilly & Co, Johnson & Johnson, Merck & Co Inc |
| HDV | iShares Core High Dividend ETF | 3 | 24.0% | Johnson & Johnson, AbbVie Inc, Merck & Co Inc |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.65% (as of 2026-07-27) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 18.67 (as of 2026-07-27) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.63% (as of 2026-06-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What XLV's Fees Cost You
XLV charges an expense ratio of 0.08% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
XLV Dividend Income Estimator
XLV currently yields 1.11%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
XLV Liquidity, Domicile & Tax Treatment
Liquidity: Quoted bid/ask spread is — and average daily volume is 10.5M/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $40.6B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: XLV is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
XLV Performance History
| Period | Return |
|---|---|
| 1-Day | +2.36% |
| 1-Week | +4.37% |
| 1-Month | +4.32% |
| 3-Month | +17.10% |
| 6-Month | +6.70% |
| YTD | +8.47% |
| 1-Year | +24.69% |
| 3-Year | +31.71% |
How XLV Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #50 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +26.69% | 0.09% | $20.4B |
| #58 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +24.69% | 0.08% | $40.6B |
| #60 | B |
XBI | State Street SPDR S&P Biotech ETF | +71.74% | 0.35% | $10.7B |
| #86 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +26.80% | 0.084% | $3.22B |
| #107 | B |
IBB | iShares Biotechnology ETF | +40.96% | 0.44% | $9.09B |
| #112 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +60.44% | 0.35% | $428M |
| #146 | B |
PPH | VanEck Pharmaceutical ETF | +29.37% | 0.36% | $879M |
| #167 | B |
IYH | iShares U.S. Healthcare ETF | +24.12% | 0.38% | $3.16B |
| #232 | C |
IHF | iShares U.S. Healthcare Providers ETF | +37.30% | 0.38% | $1.18B |
| #383 | D |
ARKG | ARK Genomic Revolution ETF | +45.46% | 0.75% | $1.73B |
| #443 | F |
IHI | iShares U.S. Medical Devices ETF | -13.86% | 0.38% | $3.02B |